OVERVIEW

Cancer Drug Development Forum (CDDF) Multi-Stakeholder Workshop 2025 is organized by Cancer Drug Development Forum (CDDF) and will be held from Mar 31 - Apr 01, 2025 at Brussels Marriott Hotel Grand Place, Brussels, Brussels, Belgium.

Description:
Diagnosis and treatment of cancer has seen a steep evolution of new treatment paradigms in the recent years. In this multi-stakeholder workshop organized by the Cancer Drug Development Forum, multidisciplinary experts will discuss key emerging treatment modalities – looking at these new developments from scientific, regulatory and practical perspectives. Novel modalities to be covered include: radiopharmaceuticals as a means to both diagnose and treat tumors; personalized vaccines as cancer immunotherapeutics; the next generation of targeted conjugates; and new approaches to tackle previously undruggable targets. In addition, cellular therapies like CAR-T cells, having become standard of care in several cancers, are still evolving, and we will cover lessons learned and the implications for new approaches on the horizon.

This multistakeholder workshop will give participants the opportunity to hear about the latest developments from hands-on experts in the field. The 1.5 day meeting consists of four plenary sessions. Panel discussions will enhance each session, always striving to involve the patient perspective, and the perspective of Regulatory Authorities. There will be time for discussion and networking, involving multiple stakeholders including industry, academics, regulatory agencies, HTAs, and, importantly, patient advocates.

Learning Objectives:
From this interactive workshop, participants will achieve the following outcomes:

To understand the latest treatment paradigms in the diagnosis and treatment of cancer
To learn about regulatory principles, including practical aspects which help regulating new modalities
To look back at what can be learned from current cutting edge treatments already authorized, enabling a wider view of how to develop new paradigms in future.